Eligibility and cost for icosapent ethyl based on the reduce-it trial: Insight from the veterans affairs healthcare system

Xiaoming Jia; Julia M. Akeroyd; Khurram Nasir; Vijay Nambi; Christie M. Ballantyne; Laura A. Petersen; Salim S. Virani

doi:10.1161/CIRCULATIONAHA.118.038691

Eligibility and cost for icosapent ethyl based on the reduce-it trial: Insight from the veterans affairs healthcare system

Xiaoming Jia
, Julia M. Akeroyd
, Khurram Nasir
, Vijay Nambi
, Christie M. Ballantyne
, Laura A. Petersen
, Salim S. Virani

Research output: Contribution to journal › Letter › peer-review

19 Citations (Scopus)

Original language	English (UK)
Pages (from-to)	1341-1343
Number of pages	3
Journal	Circulation
Volume	139
Issue number	10
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.118.038691
Publication status	Published - 5 Mar 2019
Externally published	Yes

Keywords

icosapent ethyl

Access to Document

10.1161/CIRCULATIONAHA.118.038691

Cite this

@article{b1c9d6cda5a442408ed43260c22b304b,

title = "Eligibility and cost for icosapent ethyl based on the reduce-it trial: Insight from the veterans affairs healthcare system",

keywords = "icosapent ethyl",

author = "Xiaoming Jia and Akeroyd, \{Julia M.\} and Khurram Nasir and Vijay Nambi and Ballantyne, \{Christie M.\} and Petersen, \{Laura A.\} and Virani, \{Salim S.\}",

note = "Funding Information: Dr Nasir serves on the advisory board of Regeneron. Dr Nambi serves as the site principle investigator on a study sponsored by Merck, holds a provisional patent on biomarkers for the prediction of heart failure along with Baylor College of Medicine and Roche, and is an event adjudicator on a study sponsored by Siemens. Dr Ballantyne has grant/research support (all significant; all paid to institution, not individual) from Akcea, Amarin, Amgen, Esperion, Novartis, Regeneron, Sanofi-Synthelabo, National Institute of Health, American Heart Association, and American Diabetes Association and is a consultant for Ak-cea, Amarin, Amgen, Astra Zeneca (significant), Eli Lilly, Esperion, Matinas Bi-oPharma Inc, Merck (significant), Novartis, Regeneron, and Sanofi-Synthelabo (significant). Dr Virani has grant funding from the Department of Veterans Affairs, the American Heart Association, the American Diabetes Association, and the Drs Tahira and Nuruddin Jooma Fund; receives honoraria from the American College of Cardiology (Associate Editor for Innovations ACC.org; significant) and the National Lipid Association; and serves on the steering committee for the Patient and Provider Assessment of Lipid Management (PALM) Registry at the Duke Clinical Research Institute (no financial remuneration). Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research \& Development Service Investigator Initiated Grant (IIR 16–072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), the American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and the Houston VA Health Services Research \& Development Center for Innovations grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.",

year = "2019",

month = mar,

day = "5",

doi = "10.1161/CIRCULATIONAHA.118.038691",

language = "English (UK)",

volume = "139",

pages = "1341--1343",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Eligibility and cost for icosapent ethyl based on the reduce-it trial

T2 - Insight from the veterans affairs healthcare system

AU - Jia, Xiaoming

AU - Akeroyd, Julia M.

AU - Nasir, Khurram

AU - Nambi, Vijay

AU - Ballantyne, Christie M.

AU - Petersen, Laura A.

AU - Virani, Salim S.

N1 - Funding Information: Dr Nasir serves on the advisory board of Regeneron. Dr Nambi serves as the site principle investigator on a study sponsored by Merck, holds a provisional patent on biomarkers for the prediction of heart failure along with Baylor College of Medicine and Roche, and is an event adjudicator on a study sponsored by Siemens. Dr Ballantyne has grant/research support (all significant; all paid to institution, not individual) from Akcea, Amarin, Amgen, Esperion, Novartis, Regeneron, Sanofi-Synthelabo, National Institute of Health, American Heart Association, and American Diabetes Association and is a consultant for Ak-cea, Amarin, Amgen, Astra Zeneca (significant), Eli Lilly, Esperion, Matinas Bi-oPharma Inc, Merck (significant), Novartis, Regeneron, and Sanofi-Synthelabo (significant). Dr Virani has grant funding from the Department of Veterans Affairs, the American Heart Association, the American Diabetes Association, and the Drs Tahira and Nuruddin Jooma Fund; receives honoraria from the American College of Cardiology (Associate Editor for Innovations ACC.org; significant) and the National Lipid Association; and serves on the steering committee for the Patient and Provider Assessment of Lipid Management (PALM) Registry at the Duke Clinical Research Institute (no financial remuneration). Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16–072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), the American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and the Houston VA Health Services Research & Development Center for Innovations grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.

PY - 2019/3/5

Y1 - 2019/3/5

KW - icosapent ethyl

UR - https://www.scopus.com/pages/publications/85062827848

U2 - 10.1161/CIRCULATIONAHA.118.038691

DO - 10.1161/CIRCULATIONAHA.118.038691

M3 - Letter

C2 - 30865483

AN - SCOPUS:85062827848

SN - 0009-7322

VL - 139

SP - 1341

EP - 1343

JO - Circulation

JF - Circulation

IS - 10

ER -

Eligibility and cost for icosapent ethyl based on the reduce-it trial: Insight from the veterans affairs healthcare system

Keywords

Access to Document

Other files and links

Cite this